
Coya Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| COYA | Coya Therapeutics, Inc. | 3.02 | -3.14 | -50.97% |
| Name | Price | % Change | |
|---|---|---|---|
| $3.02 | -50.97% |

Coya Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has

Reports Q3 revenue $234,134, consensus $78,570. “Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of

As of September 30, 2026, Coya had cash and cash equivalents of $35.8 million, sufficient to fund operations, as currently planned, past the Phase 2/3 ALSTARS topline data readout and

Coya Therapeutics, Inc. (COYA) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Coya Therapeutics, Inc. to post earnings of -$0.34 per share.

Coya Therapeutics (COYA) announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomized,

The latest announcement is out from Coya Therapeutics, Inc. ( ($COYA) ). On October 14, 2026, Coya Therapeutics said it will launch an open-label extension of its Phase 2/3 ALSTARS

Coya Therapeutics (COYA) announced plans to initiate an open-label extension, OLE, of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis. Coya plans to

Coya Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has

Coya Therapeutics, Inc. ( ($COYA) ) has issued an announcement. On October 5, 2026, Coya Therapeutics announced it had fully enrolled the planned 120 patients in its ongoing Phase 2/3

Coya Therapeutics (COYA) announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 23, 2027TBA | $70.37M | $-0.45 | $583.00K | -0.15 | -2.17 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.